Statistical analyses were performed using the software STATA/MP 14.0 for Windows (Stata Corp LLC, College Station, TX, USA). Binary and categorical variables are presented as percentages and numbers. Continuous variables are presented as mean ± standard deviation (SD) or median and interquartile range. The Kaplan-Meier survival curve was used to assess treatment responses after the follow-up period.
Stata mp 14.0 for windows
Manufactured by StataCorp
Sourced in United States
Stata/MP 14.0 for Windows is a statistical software package designed for data analysis, management, and visualization. It provides advanced computational capabilities to handle large datasets and perform complex statistical modeling and analysis. Stata/MP 14.0 is optimized for multiprocessor computers, allowing for faster and more efficient data processing.
Automatically generated - may contain errors
Lab products found in correlation
5 protocols using stata mp 14.0 for windows
1
Statistical Analysis of Treatment Responses
2
Survival Analysis of Prognostic Factors
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Categorical variables are presented as numbers and percentages. Continuous variables are presented using median and range. Overall survival (OS) was defined as the time from the date of diagnosis to the date of death. Event-free patients were censored on the date of their last follow-up. OS is reported as a median value expressed in years, with 95% CIs. Survival curves were estimated using the Kaplan–Meier product-limit method. The role of stratification factor was analyzed with the log-rank test. We used the Cox proportional hazards regression model to estimate hazard ratios (HRs) and relative 95% CI of potential clinical prognostic factors for OS. Important variables such as gender were included in multivariate analysis, even when univariate analysis did not identify them as significant. All tests were two-tailed and P values <0.05 were considered statistically significant. No adjustments were made for multiple comparisons. Statistical analyses were carried out with STATA/MP 14.0 for Windows (StataCorp LLP, College Station, TX, USA).
3
Survival Analysis of Clinical Outcomes
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Survival curves were generated using the Kaplan-Meier method, and for comparative differences we used the log-rank test. For Multivariable analyses we used a Cox regression model. The hazard ratio (HR) with 95% confidence interval (CI) was estimated. All reported P values were two-sided and a value <0.05 was considered significant. All analyses were conducted using Stata/MP 14.0 for Windows (StataCorp LP, College Station, TX, USA).
4
Yellow Fever Outbreak Epidemiology
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Any individual with acute onset of fever and jaundice occurrence within 14 days of onset of the first symptoms8 .
For the analysis of both definitions (Brazil and WHO), a vaccinated individual was considered as one with immunization received in, at least, 10 days from the beginning of the symptoms9 (link). Moreover, the cases with non-reported traveling to or residence in YF risk areas were included as possible exposition to sylvatic environments during the YF outbreak. Laboratorial value patterns considered to describe observed alterations were the following: thrombocytopenia with platelet count equal or under 150,000/mm3; leukopenia with leukocyte count equal or under 4,500/mm3; leukocytosis with leukocyte count equal or over 11,000/mm3; renal function alterations with serum urea values over 40mg/dL and/or creatinine over 1.3 mg/dL; hyperbilirubinemia with total bilirubin serum dosage over 2 mg/dL; and increase of twice the reference value for transaminases considering the maximum value of 40 U/L for alanine aminotransferase (ALT) and aspartate aminotransferase (AST).The significance level adopted was 5% for all hypothesis tests. Analyses were performed using SPSS for Windows v.25 and Stata/MP 14.0 for Windows software. The study used data from hospital epidemiological surveillance. The data was approved by the Ethics Committee of IIER (Protocol 024329/2018).
For the analysis of both definitions (Brazil and WHO), a vaccinated individual was considered as one with immunization received in, at least, 10 days from the beginning of the symptoms9 (link). Moreover, the cases with non-reported traveling to or residence in YF risk areas were included as possible exposition to sylvatic environments during the YF outbreak. Laboratorial value patterns considered to describe observed alterations were the following: thrombocytopenia with platelet count equal or under 150,000/mm3; leukopenia with leukocyte count equal or under 4,500/mm3; leukocytosis with leukocyte count equal or over 11,000/mm3; renal function alterations with serum urea values over 40mg/dL and/or creatinine over 1.3 mg/dL; hyperbilirubinemia with total bilirubin serum dosage over 2 mg/dL; and increase of twice the reference value for transaminases considering the maximum value of 40 U/L for alanine aminotransferase (ALT) and aspartate aminotransferase (AST).The significance level adopted was 5% for all hypothesis tests. Analyses were performed using SPSS for Windows v.25 and Stata/MP 14.0 for Windows software. The study used data from hospital epidemiological surveillance. The data was approved by the Ethics Committee of IIER (Protocol 024329/2018).
5
Survival Analysis of Oncology Patients
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Pearson's χ2 (Fisher's exact) test was used to assess measures of association in frequency tables. The equality of group medians was assessed with nonparametric tests for equality. OS, LRFS, distant metastases–free survival (DMFS), and DFS were calculated with Kaplan-Meier estimators. Statistical analysis was performed by using Stata/MP 14.0 for Windows (StataCorp LLC, College Station, TX). A P-value of .05 or less was considered statistically significant. Statistical tests were based on a two-sided significance level.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!